Dataset Information


Transcription profiling by array of H. sapeins NSCLC A549 cell line to investigate two distinct poly(ADP-ribose) polymerase (PARP) inhibitors as a hyperadditive combination effect with CDDP

ABSTRACT: Non-small cell lung cancer (NSCLC) is often treated with cisplatin (CDDP). Here, we report that two distinct poly(ADP-ribose) polymerase (PARP) inhibitors exhibited a hyperadditive combination effect with CDDP to kill NSCLC cells. A majority of CDDP-resistant cell lines and clones exhibited constitutively increased PARP expression and enzymatic activity. Cells with hyperactivated PARP initiated a DNA damage response and the intrinsic pathway of apoptosis in response to pharmacological PARP inhibition or PARP1-targeting siRNAs. Transcriptome analysis depicted an unsupervised hierarchical clustering of NSCLC cells and CDDP resistant counterparts regarding to their response to PARP inhibitors. PARP-overexpressing tumors displayed elevated levels of intracellular poly(ADP-ribose) (PAR), which predicted the response to PARP inhibitors in vitro and in vivo more accurately than PARP expression itself. Thus, CDDP-resistant cancer cells develop a dependency to PARP, becoming susceptible to PARP inhibitor-induced apoptosis.

ORGANISM(S): Homo Sapiens

SUBMITTER: justine JG guegan  

PROVIDER: E-MTAB-1353 | ArrayExpress | 2013-10-31


Dataset's files

Action DRS
E-MTAB-1353.README.txt Txt
E-MTAB-1353.idf.txt Idf Processed Raw
E-MTAB-1353.sdrf.txt Txt
Items per page:
1 - 5 of 5

Similar Datasets

2020-05-27 | PXD016997 | Pride
2015-04-10 | E-GEOD-67727 | ArrayExpress
2017-06-17 | E-MTAB-5509 | ArrayExpress
2016-06-16 | E-GEOD-83362 | ArrayExpress
2015-06-29 | E-MTAB-3266 | ArrayExpress
| S-ECPF-MTAB-1353 | BioStudies
| E-MTAB-1353 | BioStudies
2008-01-01 | E-TABM-328 | ArrayExpress
2015-09-15 | E-MTAB-3820 | ArrayExpress
2012-03-02 | E-MTAB-1013 | ArrayExpress